Windecker S, Tomii D
Summary
This editorial discusses emerging real-world evidence on the performance of the ACURATE neo2 transcatheter heart valve in routine clinical practice. Drawing on results from a multicentre post-market follow-up registry of 250 patients undergoing TAVI with ACURATE neo2, the authors highlight one-year clinical and echocardiographic outcomes, including low rates of death, stroke, and need for reintervention, as well as sustained favorable haemodynamic valve performance. The commentary frames these observational data as important preliminary insights ahead of the larger, randomized ACURATE IDE trial that will directly compare the ACURATE neo2 system with established TAVR devices.
